Business Model Breakdown
How Heartbeam Inc Makes Money
BEAT
Market Cap
$50M
Employees
16
The Short Version
Heartbeam Inc. is a medical technology company focused on developing and commercializing non-invasive, AI-driven cardiac diagnostic solutions. Its core offering, AIMIGo, utilizes proprietary 3D vector electrocardiography (VECG) to provide more precise and rapid detection of acute coronary events and arrhythmia assessment than traditional ECGs. The company aims to generate revenue by selling or licensing its FDA-cleared devices and potentially offering associated subscription services to healthcare providers, enabling improved remote patient monitoring and more accurate diagnoses in clinical and emergency settings for cardiovascular conditions.
Where the Revenue Comes From
Currently $0. Future: Device sales (e.g., AIMIGo, extended-wear patch), potentially recurring service/monitoring fees (~0% of current revenue).
Future: Licensing of proprietary VECG technology (~0% of current revenue).
Who buys: Healthcare providers including cardiologists, hospitals, emergency medical services, and potentially remote patient monitoring companies.
Why It Works (Competitive Advantages)
- ✔Proprietary 3D Vector Electrocardiography (VECG) technology for improved diagnostic accuracy.
- ✔FDA-cleared AIMIGo for certain acute cardiac events, providing a regulatory head start for this specific application.
- ✔Focus on acute and specific diagnostic challenges where current ECG may be insufficient.
Economic Moat: Narrow (Intangible Assets/IP (patented 3D VECG technology and associated FDA clearances), Switching Costs (potential for integrating their system into clinical workflows and training staff))
What Our Analysis Says
DVR Score as of May 21, 2026
Heartbeam continues to possess intriguing long-term potential anchored by its innovative 3D VECG technology and FDA-cleared AIMIGo, targeting a critical and expanding cardiovascular monitoring market. The leadership has demonstrated relevant expertise and achieved regulatory milestones. However, the company's financial state remains extremely precarious with $0 revenue in Q1 2026, a substantial net loss of $4.7 million, and a high cash burn ($3.6M in Q1 2026). While a recent $11.5 million equity raise has temporarily extended its cash runway to nearly four quarters, this comes at the cost of significant shareholder dilution. Commercialization is in its early stages ('limited commercial launch'), and there is no clear path to profitability or sustained revenue generation yet, making 10x growth highly speculative and dependent on rapid, unprecedented execution and market adoption. The explicit 'going concern' risk remains a major overhang.